PRAX – praxis precision medicines, inc. (US:NASDAQ)
Stock Stats
News
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $117.00 price target on the stock.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $105.00 price target on the stock.
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
Form DEFA14A Praxis Precision Medicin
Form DEF 14A Praxis Precision Medicin For: Jun 05
Form 8-K Praxis Precision Medicin For: Mar 27
Form 424B5 Praxis Precision Medicin
Form 424B5 Praxis Precision Medicin
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.